Oura's IPO is Femtech's Biggest Public-market Test in a Decade

Why the S-1 matters more than the filing — and what femtech operators should be watching for.

Oura Health filed confidentially for a US IPO Thursday. Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co., and Jefferies are managing the deal, with a public debut targeted for later this year. The headlines wrote themselves — $11 billion private valuation, projected $2 billion in 2026 revenue, a category Oura largely defined.

The harder question is the one the S-1 will answer. Public markets have to decide whether Oura is a consumer electronics company or a health platform. The multiples are not close.

Consumer wearables trade at 3-5x revenue at peak. Health-tech platforms with subscription economics trade at 8-12x or higher. At $2 billion in revenue, that's the difference between a $6-10 billion market cap and a $16-24 billion one. Same company, same financials, different shelf.

How Oura is priced will set the reference point for every femtech platform considering an exit in the next three years. Flo, Maven, Midi, Alloy, Kindbody, Tia — all private, all watching. None of them has had an institutional-scale public-market comparable to anchor a valuation conversation with bankers or strategic acquirers. Oura's listing creates one.

The femtech-specific signal is buried in the timing. Oura spent the past 18 months expanding into hormonal birth control support, menopause insights, and pregnancy tracking — all built into its Cycle Insights platform. Those features will be in the S-1 narrative. Whether public markets reward that women's-health positioning or treat it as a footnote will tell femtech founders something important about how Wall Street values female-specific functionality inside broader platforms.

Three things to watch when the S-1 surfaces:

The revenue mix. How much of Oura's projected $2 billion comes from subscription versus hardware. The subscription share is the multiple-driver.

The retention numbers. Membership churn is the metric public investors will underwrite. Femtech platforms with high churn (most consumer fertility and cycle apps) should be paying attention to whatever benchmark Oura sets.

The femtech-feature attribution. If the S-1 quantifies revenue or engagement tied to hormonal/menopause/pregnancy features, that's the precedent every femtech operator needs for their own pitch decks.

Oura has not disclosed share count, offering price, exchange, share-class structure, or lockup terms. The S-1 will reveal the rest. Until it lands, the filing itself is the news.

We'll cover the S-1 the moment it surfaces.